News

Sudeep Pharma Q2 Results: Revenue rises but profit down, margins narrowSudeep Pharma reports Q2 revenue growth but lower profits after Dalal Street debut. Shares of Sudeep Pharma ended higher on Friday, December 19, by 1.46% at ₹684 on the NSE.By Megha Rani  December 19, 2025, 6:53:15 PM IST (Published)2 Min ReadVadodara-based Sudeep Pharma on Friday, December 19, reported a mixed performance for the second quarter, with revenue growth offset by a drop in profitability.

The company’s net profit fell 6.15% year-on-year to ₹45.8 crore, compared with ₹48.8 crore in the same quarter last year.

EBITDA declined 11.2% to ₹55.5 crore from ₹63.5 crore a year earlier, while EBITDA margin narrowed to 34.1% from 42.7%, reflecting margin pressure during the quarter.

Revenue, however, rose 9.3% year-on-year to ₹162.7 crore, up from ₹148.8 crore in the corresponding period last year.

The results come shortly after Sudeep Pharma’s debut on Dalal Street. The company was listed on November 28, with shares opening at ₹733.95 on the BSE against an issue price of ₹593, while the stock debuted at ₹730 on the NSE.

Ahead of the listing, Sudeep Pharma’s shares were trading at a premium of about 20.4% in the unlisted market. Based on a grey market premium (GMP) of ₹121, the stock was expected to list around ₹714.

The company’s ₹895 crore initial public offering (IPO) was open for subscription between November 21-25 and saw strong investor demand. The issue was subscribed 93.72 times, attracting bids worth over ₹58,700 crore across nearly 29.86 lakh applications.

Shares of Sudeep Pharma ended higher on Friday, December 19, by 1.46% at ₹684 on the NSE.

Also Read: Suraj Estate acquires 2 parcels of land in Mumbai's Bandra for new projectsContinue Reading(Edited by : Shoma Bhattacharjee)Tagspharma sectorpharma stocksQ2 EarningsQ2 resultsrevenue